SCHEMBL4050004

SCHEMBL4050004

CCc1ccc(S(=O)(=O)O)cc1.CSc1nc(-c2ccc(Cl)cc2)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.48
KDM1A O60341 8/20 0.44
MAOA P21397 2/20 0.42
MAPT P10636 4/20 0.41
LMNA P02545 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 1/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ABL1 P00519 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4048676 0.89 PHGDH (0.48) RORCMAPTLMNANPC1RAB9A
SCHEMBL4050954 0.87 LTA4H (0.46) KDM1AMAOAMAPTLMNANPC1
SCHEMBL4050006 0.82 KDM1A (0.45) RORCKDM1AMAOAMAPTNPC1
SCHEMBL4050455 0.80 ALDH1A1 (0.40) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL4047040 0.79 RAB9A (0.56) MAPTLMNANPC1RAB9AMEN1
SCHEMBL4051455 0.76 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2NPSR1
SCHEMBL4050001 0.75 KDM1A (0.44) KDM1AMAOAMAPTLMNANPC1
SCHEMBL4051285 0.71 FBP1 (0.39) MAPTKMT2AALDH1A1
SCHEMBL2999777 0.71 SMN1; SMN2 (0.66) MAPTLMNANPC1RAB9AMEN1
SCHEMBL7251659 0.71 BCHE (0.54) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
EP-2029584-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-03-04 EP disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE RB1, RBBP5, RRM2B RORC 273/4885KDM1A 375/4885MAOA 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.